6G·

Merck acquires Verona Pharma for 10 billion dollars

Jul 09 (Reuters) - $MRK (-2,16%) Merck will buy Britain's Verona Pharma for about 10 billion dollars, the companies announced on Wednesday. The move strengthens the US company's presence in respiratory therapies as it prepares for the patent expiry of its blockbuster cancer drug.


#traderepublic Source

9
5 Commenti

immagine del profilo
I am currently building up Merck Co, in addition to Pfizer, Novo, Bristol, which I already own, and will make new highs in the future as the pipeline is strong.
3
immagine del profilo
An analyst warning about patent protection for Mavenclad briefly brought Merck shares to their knees at the beginning of the week. But the Darmstadt-based company can reassure investors.
immagine del profilo
@Smudeo I've been in the plus since today, which is a reassuring fact 😇😅
immagine del profilo
@Shem_sen In the most recent financial year, Mavenclad contributed around 5% to total sales and 12.6% to the Healthcare segment - shares that have risen steadily over the past five years.
1
immagine del profilo
@Smudeo the info is nice, but does not fit this share. You mean the German Merck share. This is the US company
1
Partecipa alla conversazione